site stats

Host reduce polytech acs trial

WebResults from HOST-REDUCE-POLYTECH-ACS Trial Reported at TCT Connect. NEW YORK – October 17, 2024 – A randomized clinical trial found that drug-eluting stents (DES) with … WebOct 17, 2024 · The aim of the HOST-REDUCE-POLYTECH-ACS (Harmonizing Optima Strategy for Treatment of coronary artery diseases – Comparison of Reduction of prasugrel or …

The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus ...

WebOct 10, 2024 · We aimed to investigate the safety and efficacy of a prasugrel-based dose de-escalation therapy. Methods: HOST-REDUCE-POLYTECH-ACS is a randomised, open-label, … WebFeb 4, 2024 · Overall, 23,637 patients (62.6%) presented as ACS, and the follow-up duration ranged from 12 to 24 months. Five trials evaluated P2Y12 inhibitor monotherapy compared with DAPT, two trials evaluated the switch from a potent P2Y12 inhibitor to clopidogrel, and one trial evaluated switching the dose of prasugrel from 10 to 5 mg. crystal in se https://xquisitemas.com

Randomized Trial Finds that Drug-Eluting Stents With Durable

WebOct 17, 2024 · HOST-Reduce-Polytech-ACS. PCI. biodegradable polymer. Hyo-Soo Kim. Up Next. Presentation TCT 2024. Monitoring in Heart Failure: Promise and Reality. Presenter: Liviu Klein. October 17, 2024. More slides + Presentation TCT 2024. ... The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents … WebAug 24, 2024 · Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial Authors WebJul 18, 2014 · Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients … dwight cook

Prasugrel dose de-escalation in diabetic patients with …

Category:Durable or Biodegradable Polymer Stent Coatings Circulation

Tags:Host reduce polytech acs trial

Host reduce polytech acs trial

TALOS-AMI - American College of Cardiology

WebNov 15, 2024 · Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE … WebSep 15, 2015 · Method/design: Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS) trial is a multicenter, randomized and open-label clinical study with a 2 × 2 factorial design, according to the type of stent (PtCr-EES …

Host reduce polytech acs trial

Did you know?

WebMethods: The HOST-REDUCE-POLYTECH-ACS trial is an investigator-initiated, randomized, open-label, adjudicator-blinded, multicenter, non-inferiority trial which compared the … WebJan 28, 2024 · This was a post-hoc analysis of the HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases—Comparison …

WebOct 19, 2024 · Results from host-reduce-polytech-ACS trial reported. A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in ...

WebSep 15, 2015 · Therefore, the HOST-REDUCE-POLYTECH-ACS trial will also provide valuable insight regarding the optimal maintenance dose of prasugrel to guarantee its potent antiplatelet effect as well as to minimize the potential hazard of bleeding complications in the Asian population. WebPrasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial

WebMar 9, 2024 · Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE …

WebTECHnology in ACS patients: HOST-REDUCE-POLYTECH-ACS trial . On behalf of the HOST-REDUCE-POLYTECH-ACS investigators. 2 . Table of Contents . 1. Investigators and Collaborators 2. Inclusion and Exclusion Criteria 3. Sample size calculation and Definition of Clinical outcomes 4. Supplementary Tables crystal insectsWebSep 8, 2024 · In die HOST-REDUCE-POLYTECH-ACS-Studie waren an 35 Kliniken in Südkorea insgesamt 2338 Patienten mit ACS aufgenommen worden, von denen 1170 der Gruppe mit Dosis-Deeskalation und 1168 der in üblicher Weise behandelten Gruppe zugeteilt waren. ... results from the HOST-REDUCE-POLYTECH-ACS trial, vorgestellt am 31.08.2024 beim … crystal insecticideWebACS patients were randomly assigned 1:1 to DP-DES or BP-DES in the HOST-REDUCE-POLYTECH-ACS trial. Complex PCI was defined as having at least 1 of the following features: ≥3 stents implanted, ≥3 lesions treated, total stent length ≥60 mm, bifurcation PCI with 2 stents, left main PCI, or heavy calcification. crystal in scottish